Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 6/20 | 0.63 |
| ▸ | NMT2 | O60551 | 5/20 | 0.63 |
| ▸ | TLR2 | O60603 | 1/20 | 0.62 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.59 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.51 |
| ▸ | GLP1R | P43220 | 3/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2339541 | 1.00 | NMT1 (0.63) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL15720614 | 1.00 | NMT1 (0.63) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL18202817 | 0.94 | NMT2 (0.59) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL2339540 | 0.91 | SIRT6 (0.64) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL2284037 | 0.91 | SIRT6 (0.64) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL15720613 | 0.91 | SIRT6 (0.64) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL22821586 | 0.91 | NMT1 (0.69) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL15720863 | 0.91 | SIRT6 (0.64) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL22821588 | 0.90 | NMT1 (0.63) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL23519401 | 0.88 | SIRT6 (0.76) | NMT1NMT2TLR2SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143835-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ADOCIA (FR) | 2017-05-25 | — | — | US | disclosed |
| EP-2920200-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE CONSISTING OF A DISCRETE NUMBER OF SACCHARIDE UNITS | Adocia (FR) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014076422-A9 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE CONSISTING OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ADOCIA (FR) | 2014-10-16 | — | — | WO | disclosed |
| US-20140187499-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ADOCIA (FR) | 2014-07-03 | — | — | US | disclosed |
| WO-2014076422-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE CONSISTING OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ADOCIA (FR) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143835-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ALG8, FUT8, UGT8 | NMT1 117/4885NMT2 202/4885TLR2 1883/4885 |
| US-20140187499-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | FUT6, FUT5, FUT8 | NMT1 46/4885NMT2 76/4885TLR2 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.